吗丁啉与四磨汤口服液联用治疗功能性消化不良临床研究

目的：分析探讨吗丁啉和四磨汤口服液联用在临床上治疗功能性消化不良的方法和疗效。方法：选取我院192例功能性消化不良患者,随机分为两组,治疗组96例,给予吗丁啉10～20mg,3次/d,四磨汤口服液20ml,3次/d,疗程均为4周。对照组96例,给予吗丁啉10～20mg,3次/d。观察治疗前、后的症状变化。结果：在治疗4周后,两组症状均有改善,治疗组的总有效率为94.7%,对照组的总有效率为75.2%,经统计治疗组与对照组总有效率差异显著,P〈0.05;结论：吗丁啉和四磨汤口服液联用,对治疗功能性消化不良疗效显著,而且不良反应少,值得在临床上推广使用。     

多潘立酮联合阿米替林治疗消化不良的效果观察

目的：探讨多潘立酮联合阿米替林治疗消化不良的临床效果,进一步指导临床治疗。方法：选取2009年1月-2012年1月本院收治的100例消化不良患者随机分为两组,每组50例,对照组给予单纯多潘立酮治疗,观察组给予多潘立酮联合阿米替林治疗,对比两组治疗疗效。结果：研究结果显示,观察组痊愈35例,有效12例,总有效率94％;对照组痊愈22例,有效17例,总有效率78％。观察组总有效率显著高于对照组,差异具有统计学意义（P〈0．05）。观察组未出现腹部痉挛、口干、腹泻、头痛和神经过敏等不良反应,仅1例女性患者出现泌乳反应;对照组出现2例腹泻症状反应。不良反应经药物减量或停药处理后均好转,未出现其他不良反应。结论：多潘立酮联合阿米替林治疗消化不良较单纯采用多潘立酮进行治疗的临床效果更佳,且安全性好,值得在临床进行推广应用。     

多潘立酮治疗慢性胃炎的临床疗效观察

目的：探讨多潘立酮缓解和改善慢性胃炎患者临床症状的疗效,为临床应用提供依据。方法：选取80例在本院消化内科接受治疗的慢性胃炎患者,随机分为两组,各40例。两组采用不同的治疗方案,对照组用药法莫替丁,观察组用药多潘立酮,对比分析两组的治疗疗效。结果：治疗两周后,对照组总有效率为77.50%,观察组总有效率为95.00%,两组比较差异具有统计学意义（P<0.05）;两组患者治疗前后症状总积分比较,治疗一周、两周后与治疗前总积分相比差异具有统计学意义（P<0.05）,观察组与对照组比较差异也具有统计学意义（P<0.05）。结论：多潘立酮可以明显的改善慢性胃炎患者的临床症状,其作用机制可能与协调胃运动、促进胃排空有关,对提高患者生活质量和指导临床治疗具有重要作用。     

多潘立酮和甲氧氯普胺治疗呃逆的临床观察

目的探讨呃逆的治疗方法。方法将呃逆患者73例按咨询顺序随机分为2组,多潘立酮组37例,给予多潘立酮10mg顿服,如1h后无效再服1次;甲氧氯普胺组36例,给予甲氧氯普胺10mg,如1h后无效再服1次。2组疗程均为1d,比较2组临床疗效。结果多潘立酮组治疗呃逆显效时间快于甲氧氯普胺组,而且疗效优于甲氧氯普胺组,差异均有统计学意义（P〈0.01）。结论多潘立酮治疗呃逆效果优于甲氧氯普胺。     

自拟香砂养胃汤治疗慢性浅表性胃炎50例

[目的]观察自拟香砂养胃汤治疗慢性浅表性胃炎的疗效。[方法]将86例符合诊断的慢性浅表性胃炎患者,随机分为治疗组50例,对照组36例。对照组予以吗丁啉片(有HP感染者配三联疗法),治疗组予以自拟香砂养胃汤治疗。[结果]治疗组50例中,痊愈26例,显效15例,有效5例,无效4例,总有效率92.00%。治疗组疗效明显优于对照组。[结论]自拟香砂养胃汤治疗慢性浅表性胃炎疗效显著。     

多潘立酮致室性心动过速1例

多潘立酮（吗丁啉）是一种外周多巴胺受体阻滞剂,临床用于治疗由胃排空延缓所致消化不良症,但因拮抗多巴胺受体,引起催乳素的释放,催乳素作用于乳腺促进乳汁分泌,故服用多潘立酮后,可引起乳房胀痛、增加泌乳、月经失调、男性乳房发育症等不良反应,偶见锥体外系反应,而引起心律失常在临床上很少见。     

多潘立酮在增强结肠运动中的作用

目的 观察多潘立酮对结肠的促动力作用,并与莫沙必利及西沙必利比较.方法 ①在体实验:将40只大鼠分为对照组、多潘立酮组、莫沙必利组和西沙必利组,每组10只.在各组大鼠近端结肠和远端结肠埋植应力传感器,记录清醒大鼠结肠运动.②离体实验:在恒温灌流肌槽中,采用张力传感器测定多巴胺和多巴胺+多潘立酮对大鼠离体结肠肌条的收缩活动.结果 在体实验:①清醒大鼠在消化间期的静息状态下,结肠呈现节律性相位收缩活动.②多潘立酮可明显增加结肠的收缩活动,使近端结肠和远端结肠平均振幅分别比对照组增加84.61%±7.26%和76.37%±8.47%,呈剂量-效应关系.同等剂量的莫沙必利对近端结肠和远端结肠平均振幅分别比对照组增加50.32%±8.16%和45.13%±7.16%.莫沙必利对结肠的促动力作用明显低于多潘立酮.而同等剂量的西沙必利对近端结肠和远端结肠平均振幅分别比对照组增加92.55%±8.37%和81.27%±9.95%,其促动力作用与多潘立酮相同.离体实验:①灌流多巴胺(40 mg/ml)可明显抑制离体结肠肌条收缩活动,较Krebs-Ringer液对照组减少91.56%±10.24%.②多潘立酮可阻断多巴胺对离体结肠肌条的舒张作用.结论 多潘立酮可明显增强结肠动力,其作用明显优于莫沙必利,并与西沙必利作用相同.多潘立酮增强结肠动力作用是通过抗多巴胺作用实现.     

Domperidone versus cisapride in the treatment of infant regurgitation and increased acid gastro-oesophageal reflux: a pilot study

Aim: Although domperidone is used frequently to treat infant regurgitation, efficacy data are scarce. Cisapride was previously used in the same indication.
Methods: Domperidone and cisapride were compared in an investigator-blinded, prospective comparative trial by evaluating (a) the frequency of regurgitation, (b) acid reflux and (c) cardiac side effects in infants regurgitating >4 times/day since >2 weeks and with reflux-associated symptoms of discomfort, after conservative treatment failure.
Results: Within the first treatment week, the frequency of regurgitation decreased in both groups, more rapidly in the cisapride group: the median regurgitation decreased from 6.22 to 3.50 in the cisapride group versus from 4.80 to 3.70 in the domperidone group. The decrease in regurgitation was still significant after 1 month: cisapride from 6.22 to 1.55 versus domperidone from 4.80 to 1.25. However, the natural decrease in the incidence of regurgitation induced by age should also be considered. The median reflux index decreased after 1 month in the cisapride group from 3.60 to 1.75 versus from 2.70 to 2.45 in the domperidone group. One child treated with cisapride developed a significant QT prolongation.
Conclusion: The decrease in regurgitation was comparable in both groups, although acid reflux decreased more in the cisapride group. Cisapride induced QT prolongation in one infant.     

雷贝拉唑联合多潘立酮治疗FD的临床研究

目的:评价雷贝拉唑联合多潘立酮治疗功能性消化不良(FD)的临床疗效。方法:雷贝拉唑联合多潘立酮治疗FD患者30例,为治疗组;单用多潘立酮治疗FD患者30例,为对照组。结果:治疗组与对照组的总有效率分别为86.7%和43.3%(P<0.05)。两组患者治疗后均未发现不良反应。结论:雷贝拉唑联合多潘立酮能有效缓解FD的症状,是治疗FD安全、有效的方法。     

Pharmacologically specific pretreatment effects on apomorphine-mediated conditioned taste aversions in rats

Pretreatment with pimozide (0.2-1.2 mg/kg) reduced a conditioned taste aversion produced by apomorphine (0.4 mg/kg) in a dose-related manner. This pretreatment effect was pharmacologically specific as shown by the inability of pimozide to prevent a conditioned taste aversion produced by nicotine (0.4 mg/kg). The results argue against the hypothesis that "proximal pre-exposure" effects are always non-specific and indicate that further pharmacological characterisation of drug-induced conditioned taste aversion may be possible. Pretreatment with a peripherally-acting antiemetic compound, domperidone, did not prevent apomorphine producing conditioned taste aversions. These data suggest that conditioned taste aversions produced by apomorphine are mediated through central dopamine receptors unrelated to the emetic properties of apomorphine and are not a result of conditioned nausea.